Patheon is supporting development of two Boehringer Ingelheim type II diabetes treatments in a three-year, $18m (€13m) deal.
Canada-based Patheon will provide services to help develop two fixed-dose combination products. Boehringer is developing the products for type II diabetics. Further details of the role Patheon will have in development are yet to emerge.
“I am very gratified that Boehringer Ingelheim recognizes our expertise in formulating, scaling and successfully launching complex formulations such as these molecules”, Mark Kontny, president of pharmaceutical development services and chief scientific officer at Patheon, said.
Patheon expects demand for development services to grow as biopharm cuts in-house capacity. As part of its reorganisation Patheon plans to invest in earlier stage development capabilities and Europe.